• Record Fourth Quarter 2016 Revenue is estimated to be at least $24.5 million which represents 10.0% year on year growth
• Full Year 2016 Revenue is estimated to be at least $90.0 million which represents 4.1% year on year growth
• Fourth Quarter 2016 Adjusted EBITDA* is estimated to be at least $1.25 million versus a loss of $350,000 in the Fourth Quarter of 2015
• Full Year 2016 Adjusted EBITDA* is estimated to be at least $2.2 million versus a pro f…

Belgrade, MT, November 22, 2016 – Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Xsert Lumbar Expandable Interbody System.

The Xsert System is an all titanium expandable interbody device that expands in-situ. It is available in various sizes and lordotic angulations to fit the most complex anatom…

BELGRADE, Mont., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of its rights offering (the "Offering") of units at a subscription price of $0.75 per unit, for aggregate gross proceeds to the Company of approximately $3.8 million.

Pursuant to the Rights Offering, Xtant sold an aggr…

BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that the subscription period for its previously announced rights offering (the "Offering") of units at a subscription price of $0.75 per unit expired on November 14, 2016, and these rights are no longer exercisable.

Based on the r…

Belgrade, MT, November 15, 2016 – Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Irix-C cervical cage for use with autograft and/or allograft and the expansion of the range of levels allowable from C3-T1 to C2-T1. Previously the device was cleared only for use with autogenous bone graft. This furthers…

BELGRADE, Mont., June 16, 2016 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Paul Buckman, Eric Timko, and Rudy Mazzocchi to its Board of Directors.  The Company also announced the resignation of Directors Jon Wickwire and David Goodman.  The above changes will be effective as of July 2, 2016.

Paul Buckman has more than …

BELGRADE, Mont. and DALLAS, June 08, 2016 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices and Pinnacle Spine Group, LLC, a developer of innovative spinal fusion solutions, today announced a joint agreement to expand distribution of Pinnacle’s InFill® Lateral Lumbar Interbody Fusion System. Through this agreement, Xtant enters the lateral lumbar interbody fusion …

New facility provides additional working capital to continue Company market expansion plans

BELGRADE, Mont., May 26, 2016 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced the completion of an accounts receivable revolver credit facility with Silicon Valley Bank to provide up to $6 million in funds t…

BELGRADE, Mont., May 17, 2016 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerlyBacterin International Holdings, Inc., a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that its Chief Executive Officer, Dan Goldberger will be presenting at the following conferences: 17th Annual B. Riley & Co. Investor Conference The Company will be presenting at the 17th Ann…

BELGRADE, Mont., May 13, 2016 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, has established a record date for its 2016 annual meeting of stockholders. Xtant Medical stockholders of record at the close of business on May 23, 2016 will be entitled to notice of the annual meeting and to vote upon matters considered at the meeting. The annual meeting is s…